Market Place
Sourcing Support
Alzamend Neuro to Present Data at Society of Toxicology 2025
18 Dec 2024 //
BUSINESSWIRE
Alzamend Neuro Reports Q2 2025 Results, Updates Clinical Programs
12 Dec 2024 //
BUSINESSWIRE
Alzamend Reports Lithium Exposure Study in Alzheimer’s Mice
19 Nov 2024 //
BUSINESSWIRE
Alzamend Neuro Presents Phase IIA Data For Alzheimer’s Dementia
16 Oct 2024 //
BUSINESSWIRE
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
15 Oct 2024 //
BUSINESSWIRE
Alzamend CEO Participates Maxim Group`s Virtual Healthcare Conference
10 Oct 2024 //
BUSINESSWIRE
Alzamend Neuro Issues Letter to Stockholders
26 Aug 2024 //
BUSINESSWIRE
Alzamend Partners With MGH For AL001 Phase II Trial In PTSD Patients
19 Aug 2024 //
BUSINESSWIRE
Alzamend Partners With MGH For AL001 Phase II Depression Trial
12 Aug 2024 //
BUSINESSWIRE
Alzamend Partners With MGH For AL001 Phase II Bipolar Disorder Trial
06 Aug 2024 //
BUSINESSWIRE
Alzamend Neuro And MGH Partner For AL001 Alzheimer`s Trial
05 Aug 2024 //
BUSINESSWIRE
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
31 Jul 2024 //
BUSINESSWIRE
Alzamend Neuro Announces Reverse Stock Split
12 Jul 2024 //
BUSINESSWIRE
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
22 May 2024 //
BUSINESSWIRE
Alzamend Neuro Announces Initial Closing of Private Placement
14 May 2024 //
BUSINESSWIRE
Alzamend Neuro $25M Registered Direct, Private Placement
09 May 2024 //
BUSINESSWIRE
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
07 May 2024 //
BUSINESSWIRE
Alzamend Receives FDA “Study May Proceed” Notification for PhIIA Trial of AL001
11 Dec 2023 //
BUSINESSWIRE
Alzamend Receives FDA “Study May Proceed” Notification for Ph IIA Trial of AL001
20 Nov 2023 //
BUSINESSWIRE
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
16 Nov 2023 //
BUSINESSWIRE
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in AL001
13 Nov 2023 //
BUSINESSWIRE
Alzamend Neuro Announces Reverse Stock Split
30 Oct 2023 //
BUSINESSWIRE
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial of AL001
23 Oct 2023 //
BUSINESSWIRE
Alzamend Receives FDA Notification for a Phase IIA Clinical Trial of AL001
02 Oct 2023 //
BUSINESSWIRE
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance
22 Sep 2023 //
BUSINESSWIRE
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001
30 Aug 2023 //
BUSINESSWIRE
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
22 Jun 2023 //
BUSINESSWIRE
Alzamend Neuro CEO Stephan Jackman to Participate at the Maxim Group Conference
13 Jun 2023 //
BUSINESSWIRE
Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Trial
14 Apr 2023 //
CONTRACT PHARMA
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for ALZN002
03 Apr 2023 //
BUSINESSWIRE
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA for AL001
22 Mar 2023 //
BUSINESSWIRE
Alzamend Neuro Reports Third Fiscal Quarter Financial Results
16 Mar 2023 //
BUSINESSWIRE
Alzamend Neuro to Present at Sequire Biotechnology Conference
26 Jan 2023 //
BUSINESSWIRE
Alzamend Partners With Biorasi to Conduct a Parallel Group Phase I/IIA Trial
04 Jan 2023 //
BUSINESSWIRE
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network
15 Nov 2022 //
BUSINESSWIRE
Alzamend Announces Addition of Healthy Subjects to PhIIA Trial for AL001
06 Oct 2022 //
BENZINGA
Alzamend Neuro Announces Addition of Healthy Subjects to PIIA Trial for AL001
05 Oct 2022 //
BUSINESSWIRE
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for ALZN002
29 Sep 2022 //
BUSINESSWIRE
Alzamend Has Regained Compliance with Nasdaq`s Minimum Bid Price Requirement
22 Sep 2022 //
BUSINESSWIRE
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001
18 Jul 2022 //
BUSINESSWIRE
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
03 Jun 2022 //
BUSINESSWIRE
Alzamend Neuro Announces Pre-IND Submission for AL001 for BD, MDD and PTSD
17 May 2022 //
BUSINESSWIRE
Alzamend Neuro Initiates PIIA Multiple Ascending Dose Trial for AL001
05 May 2022 //
BUSINESSWIRE
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power
28 Apr 2022 //
BUSINESSWIRE
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta for AD
11 Apr 2022 //
BUSINESSWIRE
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
04 Apr 2022 //
BUSINESSWIRE
Alzamend Neuro Announces Full Data Set From Phase 1 Trial for AL001
28 Mar 2022 //
BUSINESSWIRE
Alzamend Neuro Announces Positive Topline Data from Phase 1 Trial for AL001
17 Dec 2021 //
BUSINESSWIRE
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002
30 Sep 2021 //
BUSINESSWIRE
Alzamend Neuro Announces Initiation of PI First-in-Human Clinical Trial of AL001
13 Sep 2021 //
BUSINESSWIRE
Alzamend Neuro and Altasciences to conduct a Phase I study for AL001.
17 Aug 2021 //
BUSINESSWIRE
Alzamend Neuro Investment Under Its Investigational NDA for AL001
04 Aug 2021 //
BUSINESSWIRE
Alzamend Neuro Announces Pre-IND Submission for AL002
30 Jul 2021 //
BUSINESS WIRE
Alzamend Neuro Gets FDA Study May Proceed Letter for AL001 for Dementia in AD
29 Jul 2021 //
BUSINESSWIRE
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study
23 Jul 2021 //
BUSINESSWIRE
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
12 Jul 2021 //
BUSINESSWIRE
Alzamend Neuro Submits IND Application for AL001
01 Jul 2021 //
BUSINESSWIRE
Alzamend Neuro Announces Closing of Initial Public Offering of $14.4 Million
17 Jun 2021 //
BUSINESSWIRE
